Флугесик

Quick links to important sections

Флугесик

Selected form

Method of action: Analgesic, Antipyretic

Treatment option: Pain

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Флугесик

Property Description
Active ingredient Flupirtine maleate
Form Capsules, tablets, suppositories, injectable solution
Pharmacological class Non-opioid centrally acting analgesic (SNEPCO)
Common use Relief of moderate-to-severe pain, especially with muscle tension
Origin Synthetic (triaminopyridine derivative)

Флугесик: Classification and Definition

Флугесик is a single-ingredient, synthetic pharmaceutical preparation whose active substance is Flupirtine (INN), typically formulated as the maleate salt. This medicine is formally classified as a centrally acting analgesic, a property that distinguishes it from peripherally acting compounds like traditional over-the-counter pain relievers. Flupirtine belongs to a unique pharmacological class, distinct from common treatments like opioids and NSAIDs, known as Selective Neuronal Potassium Channel Openers (SNEPCOs). Flupirtine's property is its ability to stabilize the electrical potential of nerve cells, as it operates via an unconventional pathway compared to most other analgesics.

Composition and Available Forms

The core composition of Флугесик is exclusively the active compound, Flupirtine maleate. As a single-entity drug, it is manufactured in several dosage forms for different routes of administration. These forms include immediate-release capsules and modified-release tablets for oral intake, suppositories for rectal use, and aqueous solutions for intravenous injection. This range of presentations, including modified-release forms, is provided for continuous pain management.

General Therapeutic Purpose

The general therapeutic purpose of Флугесик is the management of moderate-to-severe pain. Flupirtine provides analgesia (pain relief) alongside an accompanying skeletal muscle relaxant property. This dual action is utilized for pain scenarios where discomfort is accompanied by associated muscle tightening or spasm. This characteristic positions the medicine as an option for generalized pain where reduction of tension is a factor.

What side effects are possible with Флугесик?

Possible side effects and safety information: Flupirtine

The officially documented safety profile for Flupirtine is characterized by a central risk of hepatotoxicity (liver injury) alongside other common adverse reactions, as classified by regulatory authorities like the European Medicines Agency (EMA).


Serious Adverse Reactions and Key Constraints

The most significant concern documented in regulatory labeling is the risk of serious liver injury, which includes officially reported cases of Hepatitis and Acute Liver Failure. Due to this risk, the medicine is formally contraindicated (must not be used) in individuals with pre-existing liver disease, severe hepatic impairment, or chronic alcohol abuse.

To manage this risk, official regulations impose strict constraints:

  • Duration Limit: Treatment is restricted to a maximum of 14 days, as the risk of liver injury is documented to increase with longer exposure.
  • Mandatory Monitoring: Weekly liver function tests are required throughout the course of treatment.

Frequency-Classified Adverse Reactions

The official classifications group other possible side effects based on their documented frequency:

Classification System-Organ Class Examples of Documented Effects
Very Common Hepatobiliary Disorders Increased transaminases (elevated liver enzymes)
Common Nervous System Disorders Dizziness, drowsiness, headache
Common Gastrointestinal Disorders Nausea, vomiting, diarrhea, constipation, abdominal discomfort
Uncommon Psychiatric Disorders Depression, sleep disorders

These safety classifications align with the regulatory frequency framework used to communicate potential risks to the public.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

The regulatory profile for Flupirtine maleate overdose highlights the risk of severe hepatotoxicity, which can lead to acute liver failure. This serious outcome has been documented as requiring liver transplantation or resulting in a fatal outcome, making it the primary life-threatening risk. Acute overdose generally presents with a cluster of Central Nervous System (CNS) effects and Gastrointestinal (GI) symptoms. Documented acute manifestations include drowsiness, dizziness, ataxia (lack of muscle coordination), muscle tremor, nausea, and vomiting.

When Immediate Medical Help is Required

Regulatory authorities explicitly mandate that individuals must seek immediate medical attention upon the observation of any signs of liver disorder. These critical signs include the appearance of jaundice, dark urine, pronounced fatigue, or abdominal discomfort. The medication must be discontinued immediately when any clinical or laboratory indication of liver dysfunction is identified.

Due to the severity of potential hepatic risk, any overdose situation is considered an emergency that requires management in a hospital setting under close monitoring. No specific antidote is listed in the official prescribing information, meaning treatment focuses entirely on symptomatic and supportive care. Individuals with pre-existing liver disease or chronic alcohol use have a documented increased risk for severe hepatic reaction.

Therapeutic Uses of Флугесик

What Флугесик treats: Main Uses and Benefits

This medicine is applied across domains where additional symptomatic support is needed for acute pain in adults in situations where other symptomatic options may not be appropriate. This sets the primary context for its use, focusing on scenarios where additional symptomatic assistance is needed.

The medication is commonly used to help with managing symptoms related to physical discomfort that involve a significant muscular component. It is relevant for addressing symptoms that create noticeable physiological strain in conditions presenting with systemic or localized discomfort, such as low-back pain, musculoskeletal pain, muscle strain, tension headaches, and nerve-related pain (e.g., neuralgia). It is also applied in clinical settings that involve acute or unstable symptom patterns, including post-operative pain and conditions like dysmenorrhoea.

Its use is considered relevant for easing symptoms that interfere with daily comfort. This application is seen in its supportive role for managing both the pain and the associated muscle tightness, which supports general well-being during symptomatic phases. It contributes to easing the overall symptom load and assists with maintaining functional stability when symptoms create noticeable physiological strain.

Quick Fact: Symptomatic Support for Pain and Tension
Primary Domain: Pain management, especially with muscle tension.
Core Benefit: Contributes to easing the overall symptom load related to pain and muscle spasm.
Key Scenarios: Acute episodes, post-operative care, and chronic conditions like LBP.
Patient Relevance: Applied in contexts where additional symptomatic support is needed.

Regulatory References

  1. European Medicines Agency Assessment Report

Eligibility and Restrictions for Use

Who can and cannot use Флугесик?

The official eligibility profile for Flupirtine maleate is highly restrictive, focusing on short-term use in adults and imposing several absolute contraindications based on patient health status, as detailed in regulatory documents.

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults (18 years and older) with acute (short-term) pain whose treatment duration must not exceed 2 weeks and only if treatment with other analgesics (e.g., NSAIDs, weak opioids) is contraindicated.
Populations for whom use is contraindicated Patients with any pre-existing liver disease (including chronic liver disease, cholestasis, or hepatic encephalopathy), myasthenia gravis, chronic alcoholism, or known hypersensitivity to flupirtine maleate.
Age-related eligibility rules Use is not established and not recommended in children and adolescents under 18 years of age.
Pregnancy and lactation eligibility status Not recommended during pregnancy or lactation.

Eligibility-Related Restrictions

Category Official Regulatory Statement
Comorbidity/Condition Limitations The medicine is contraindicated in patients taking other hepatotoxic medicines. Conditional use is required for older adults and patients with renal impairment, typically requiring a dose reduction.

Connection to the overall eligibility profile: Official regulatory documents strictly define eligibility by imposing absolute exclusions based on liver health and neuromuscular status. The entire profile limits authorized use to a narrow, short-term context for adults who cannot use alternative, first-line pain treatments, ensuring use is confined to the specific population where its risk-benefit profile is deemed acceptable.

What should I know about interactions with other medicines?

This section details the officially documented interaction profile for Flupirtine maleate as established by government regulatory sources.

Contraindicated and High-Risk Combinations

The primary regulatory concern for Flupirtine involves the potential for enhanced liver injury risk (hepatotoxicity). This leads to specific restrictions on co-administration:

  • Contraindicated Medicines: The use of Flupirtine is formally prohibited with other medicinal products known to cause liver damage (hepatotoxic drugs), such as Paracetamol (Acetaminophen), due to the risk of severe, additive liver toxicity.
  • Population Restriction: Flupirtine is contraindicated in patients with pre-existing liver disease or chronic alcohol abuse, as these conditions significantly heighten the population-specific risk associated with the drug's interaction profile.

Interactions Requiring Monitoring or Caution

Other clinically significant interactions are documented, leading to requirements for monitoring or heightened caution:

Interacting Substance Category Official Regulatory Constraint
Oral Anticoagulants (e.g., Warfarin) Requires mandatory and regular monitoring of Prothrombin Time (blood coagulation times) due to the risk of potentiating the anticoagulant effect.
Other Sedatives (e.g., Benzodiazepines) May result in potentiated CNS effects, specifically increased tiredness and dizziness.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Co-administration may significantly increase the severity of hepato-biliary reactions.
Alcohol Must be limited or avoided due to the additive risk of CNS potentiation and aggravation of liver toxicity risk.

No timing separation requirements are documented in the official regulatory prescribing information.

Mechanism of Action

How Флугесик Works

Флугесик operates through the mechanism of selective calcium channel inhibition, acting as a channel blocker primarily on the L-type voltage-gated calcium channels located within vascular smooth muscle cells. This interaction prevents the essential influx of extracellular calcium ions ( Ca^2+) into the smooth muscle cytoplasm.

The interruption of calcium entry leads to a decrease in the concentration of available intracellular Ca^2+. This shortage inhibits the Ca^2+-dependent phosphorylation required for the actin-myosin contractile cycle. The subsequent loss of contractility causes the smooth muscle tissue of blood vessels to relax, resulting in vasodilation (widening of the vessels).

At a systemic level, this relaxation and widening of peripheral arteries directly leads to a reduction in overall systemic vascular resistance. This pathway modulation alters the impedance to blood flow and the pressure gradient within the circulatory system, contributing to the drug's physiological profile of modified vascular dynamics.

Dosage and Administration Information

Administration Routes and Standard Dosing

The usage of Флугесик is characterized by several administration routes and dosage forms. The medicine is available for oral intake as immediate-release (100 mg) and modified-release (400 mg) tablets, for rectal use as suppositories, and as an intramuscular injection. Standard oral administration of the immediate-release form is 100 mg, taken three or four times daily. The 400 mg modified-release tablet is administered once daily and must be swallowed whole without crushing or chewing to maintain the controlled-release properties.


Mandatory Use Constraints and Duration

The total dose administered across all forms must not exceed 600 mg per day. A critical requirement is the total duration of therapy: treatment must not exceed 2 weeks (14 days). The drug is intended for use at the lowest effective dose for the shortest duration necessary. Furthermore, administration is restricted to cases where treatment with alternative analgesics, such as non-steroidal anti-inflammatory drugs or weak opioids, is contraindicated.


Population-Specific Rules

Dosage for older adults or patients with renal or hepatic impairment involves a 50% reduction from the standard adult dose. The medicine is not recommended for use in individuals under 18 years of age, as safety and efficacy have not been established in this population.

Recent Clinical Evidence

Research evidence / Overview of studies for Флугесик

Evidence for Use in Musculoskeletal Pain and Muscle Tension

The evidence base for Flupirtine (Флугесик) primarily consists of randomized controlled trials (RCTs) and systematic reviews that have examined the medicine in contexts involving periods of heightened symptoms, such as low back pain (LBP) and other painful disorders where muscle spasm was a factor. This medicine was evaluated in studies examining patient-reported experiences related to outcomes related to physical discomfort. Researchers conducted comparative trials, often observing how symptoms evolved in the studied populations against other active treatments.

Research explored short-term symptom changes, focusing on outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. Findings describe patterns observed in the studies related to measurements of pain intensity and muscular tenseness over short defined time intervals. What remains uncertain is the information for long-term outcomes; evidence is limited for use beyond a short-term period, typically 14 days, and data for chronic pain management remains insufficient.


Evidence for Use in Acute Pain and Post-Operative Settings

Flupirtine was evaluated in contexts of short-term, acute symptom patterns, which includes the context of post-operative pain management. The outcomes researchers examined included the severity of physical discomfort and the patient’s need for supplementary pain medication. Findings indicate patterns related to short-term changes that were observed in some comparative trials. The outcomes related to physical discomfort of the medicine in the acute perioperative pain setting were described as mixed or inconsistent in some systematic reviews.

Research highlights changes measured during the study period, but the regulatory context notes that this medicine is primarily applied in research exploring short-term symptom changes, especially in situations where other symptomatic options are not considered appropriate.


Long-Term Studies and Durability of Response

The majority of pivotal RCTs and comparative studies relevant to regulatory assessment were designed to examine outcomes over short periods, often not exceeding four weeks. As a result, long-term effects are not fully established. There is limited information for long-term outcomes regarding how symptoms evolve in the observed populations during extended treatment, and research does not determine whether long-lasting symptom changes were experienced by an individual. The available data primarily describe group patterns observed in studies with short follow-up durations.

Frequently Asked Questions (FAQ)

Common questions about Флугесик (FAQ)

Q: Are there any common foods or drinks that should be avoided when taking Флугесик?

Official product information indicates that alcohol is recommended to be limited or avoided while using this medicine. This constraint is noted because alcohol can add to the risk of central nervous system effects, such as drowsiness, and may also worsen the risk of liver toxicity associated with the drug. Consult the detailed patient information provided regarding food and drink constraints.


Q: Is there any research looking at the use of Флугесик in older adults?

Regulatory guidelines indicate special consideration for older adults, including that a 50% reduction in the standard adult dose is typically necessary. This adjustment is based on studies examining how the body processes and clears the medicine in this population. This reflects the differences noted in drug clearance for this age group.


Q: Can Флугесик be taken at the same time as cold and flu medicine?

Official documents state that this medicine is contraindicated (formally prohibited from use) alongside any other medicinal products known to cause liver damage (hepatotoxic drugs). This specifically includes Paracetamol (Acetaminophen), a common ingredient in cold and flu preparations. Combining these substances is associated with an increased risk of severe liver toxicity.


Q: Why is it important to check my kidney health before starting Флугесик?

Kidney health status is important because this organ plays a role in clearing the drug from the body. Regulatory documents note that a 50% reduction in dose is typically required for patients with renal (kidney) impairment. This modification is based on concerns regarding drug clearance in this population.


Q: Do I need to avoid driving or operating machinery after taking Флугесик?

Official regulatory warnings state that the medicine commonly causes side effects such as dizziness and drowsiness. Due to these possible effects, the ability to drive or operate complex machinery may be impaired while the drug is in the system. This is a standard warning for medications that affect the central nervous system.


Q: What does the term 'contraindication' mean in relation to Флугесик?

The term 'contraindication' is used in official documentation to describe a condition or circumstance where the drug's use is formally prohibited. For Флугесик, this includes conditions like pre-existing liver disease or myasthenia gravis. The use of the medicine despite a contraindication is associated with a heightened risk of adverse outcomes.


Q: Do I need to eat food when I take Флугесик?

Regulatory information indicates that administration with meals is often suggested to help reduce common gastrointestinal side effects such as nausea or stomach upset. The drug is reported to be absorbed by the body regardless of whether it is taken with food or on an empty stomach.


Q: How quickly does Флугесик usually start working?

Pharmacokinetic data indicate that the drug reaches its maximum concentration in the bloodstream, known as the peak concentration, at approximately 1.6 to 2 hours after an oral dose. This measurement of time to peak concentration is often used to characterize the drug's absorption and activity profile.


Q: Is Флугесик a common treatment for nerve pain?

The officially approved therapeutic indication for this medicine is strictly limited to the treatment of acute pain in adults when other analgesic options are not appropriate. While studies have examined the drug's effects on nerve cells, neuropathic pain (nerve pain) is not listed as an approved indication in current regulatory documents.


Q: Is Флугесик considered habit-forming?

Regulatory reviews generally report that this medicine has no addictive properties and is not classified as an opioid. However, official regulations restrict the total duration of treatment to a maximum of 14 days. This restriction serves to minimize the potential for dependency associated with prolonged use.


Q: Can Флугесик be used for menstrual cramps?

Regulatory reports note that the medicine has been historically examined in contexts involving various types of pain, including menstrual (period) pain. However, the current officially approved therapeutic indication is restricted to the management of acute pain in adults when alternative treatments are deemed unsuitable.


Q: If I have a history of ulcers, is Флугесик something I cannot use?

A history of ulcers is not listed as an absolute contraindication in major regulatory documents. However, some patient safety summaries highlight that its use may warrant caution in patients with a history of peptic ulcers. This consideration is related to the possibility of the drug aggravating general gastrointestinal side effects.


Q: Is Флугесик an anti-inflammatory drug?

No, the medicine is classified as a centrally acting analgesic, meaning its primary action is on the central nervous system. Regulatory and pharmacological descriptions confirm that the drug possesses no antiphlogistic, or anti-inflammatory, properties. Its primary documented actions are pain relief and muscle relaxation.


Q: Does taking Флугесик make other medications less effective?

The official Interactions section in regulatory documents primarily details the risk of the drug increasing the effects or risks of other medicines, such as sedatives or anticoagulants. The available safety information does not explicitly document instances where Флугесик causes other co-administered medications to become less effective.


Q: Is Флугесик recommended for pain related to common headaches?

While regulatory reports indicate the medicine has been historically used to treat types of primary headache, the currently approved therapeutic indication is restricted. Its use is limited to managing acute pain in adults when other standard analgesics are deemed inappropriate.


Q: If I stop taking Флугесик suddenly, are there expected side effects?

Regulatory guidelines strictly limit treatment to a maximum of 14 days, which is intended to minimize the risk of dependency. Case reports associated with prior long-term use (now prohibited) found that abrupt cessation could lead to withdrawal symptoms, such as sweating, tremors, and sleep disorders.


Q: What is the legal status of Флугесик (e.g., prescription-only or over-the-counter)?

The medicine is classified as a prescription-only drug in all authorized countries where it is approved. It is not available for purchase over-the-counter and requires authorization from a licensed healthcare provider.


Q: How long does the pain relief from one dose of Флугесик typically last?

The duration of pain relief from a single dose is related to the drug's presence in the body. Pharmacokinetic data show that the average half-life of the drug is approximately 6.5 hours in healthy individuals. The half-life measurement helps characterize the drug's duration profile in the system.

How should Флугесик be stored and disposed of?

How to Store and Dispose of Флугесик?

The official storage and disposal requirements for Флугесик (Flupirtine maleate) define strict conditions for product stability and environmental protection.

Storage/Disposal Domain Official Regulatory Requirements
Storage Conditions Store in a dry and well-ventilated place, protected from light. Specific low-temperature ranges (e.g., 2-8 C) may apply to the pure substance or certain formulations.
Container Requirements The container must be kept tightly closed at all times to maintain product integrity and stability.
Disposal Requirements Disposal of contents and containers must be performed in accordance with local, regional, and national regulations.
Environmental Protection Do not allow the product to enter sewers, surface water, or ground water. The medicine must not be discarded with regular household garbage.

The required storage environment focuses on stability control, mandating that the medicine be stored in a dry place protected from light. This is reinforced by the requirement to keep the container tightly closed. Disposal must adhere to specific Mandatory Waste Management rules, which strictly prohibit discharge into water systems and require compliance with official pharmaceutical waste collection procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Флугесик found in:

A-Z Index: